---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-25-000192"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:28:37.005576+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lexaria reduces at-the-market equity facility from $20M to $5M

## Summary
- Amended Capital on Demand Sales Agreement with JonesTrading; maximum aggregate principal amount reduced to $5M from $20M.
- Shares sold under new registration statement on Form S-3 (333-284407), effective Jan 30, 2025.
- Agent commission remains 3.0% of gross sales price; customary indemnification and expense reimbursement.
- Offering terminates upon sale of all Shares or termination of agreement by either party.

## SEC filing metadata
- accession: 0001640334-25-000192
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033425000192/0001640334-25-000192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033425000192/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-25-000192
- JSON: https://secwatch.observer/filing/0001640334-25-000192.json
- Plain text: https://secwatch.observer/filing/0001640334-25-000192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.